Status:
UNKNOWN
THE ROLE OF CARDIAC MARKERS IN HYPOXIC ISCHEMIC ENCEPHALOPATHY IN LONG-TERM NEURODEVELOPMENTAL FOLLOW UP
Lead Sponsor:
Hacettepe University
Conditions:
Hypoxic-Ischemic Encephalopathy
Newborn Morbidity
Eligibility:
All Genders
Up to 28 years
Brief Summary
In this study, the correlation of cardiac marker values (Troponin I, CK, CK-MB) measured before treatment with the long-term neurodevelopmental score of newborns diagnosed with perinatal asphyxia and ...
Detailed Description
With therapeutic hypothermia, it is aimed to reduce the temperature of brain structures and basal ganglia to 32- 34 degrees for 72 hours. The mechanism of action of hypothermia can be listed as decrea...
Eligibility Criteria
Inclusion
- Babies who have been hospitalized in the Neonatal Intensive Care Unit of Hacettepe University İhsan Doğramacı Children's Hospital, have received therapeutic hypothermia treatment for perinatal asphyxia and are discharged and have neurodevelopmental assessments during their follow-up will be taken.
Exclusion
- Babies with chromosomal abnormalities Major congenital anomaly (congenital heart disease, lung anomaly, congenital diaphragmatic hernia, spina bifida etc.) Babies with inherited metabolic diseases • Babies with congenital muscle disease-hypotonicity
Key Trial Info
Start Date :
December 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04766541
Start Date
December 30 2020
End Date
June 30 2021
Last Update
February 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Umit Ayse Tandircioglu
Ankara, Turkey (Türkiye), 06230